Open AccessEffect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease
Author(s) -
Elisa Fabbrini,
B. Selma Mohammed,
Kevin Korenblat,
Faidon Magkos,
Jennifer McCrea,
Bruce W. Patterson,
Samuel Klein
Publication year - 2010
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2009-2622
Subject(s) - fenofibrate , medicine , endocrinology , very low density lipoprotein , triglyceride , hypertriglyceridemia , apolipoprotein b , nonalcoholic fatty liver disease , lipoprotein , fatty acid , niacin , fatty liver , chemistry , cholesterol , biochemistry , disease
Nonalcoholic fatty liver disease is associated with risk factors for cardiovascular disease, particularly increased plasma triglyceride (TG) concentrations and insulin resistance. Fenofibrate and extended release nicotinic acid (Niaspan) are used to treat hypertriglyceridemia and can affect fatty acid oxidation and plasma free fatty acid concentrations, which influence intrahepatic triglyceride (IHTG) content and metabolic function.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom